Company: HMDCF
Filing Date: 2025-03-19
Form Type: 20-F
Source: 0001410578-25-000377
Chunk: 641

Company: HUTCHMED (China) Ltd
Filing Date: 2025-03-19
Form: 20-F
Item: Item 16K
Chunk 641
---
 Consolidated Statements of Comprehensive Income/(Loss)                                       F- 7   
  Consolidated Statements of Changes in Shareholders ’ Equity                                  F- 8   
  Consolidated Statements of Cash Flows                                                        F- 9   
  Notes to the Consolidated Financial Statements                                               F- 10  
  Audited Consolidated Financial Statements of Shanghai Hutchison Pharmaceuticals Limited             
  Report of Independent Auditors                                                               F- 57  
  For the Years Ended December 31, 2024, 2023 and 2022:                                               
  Consolidated Income Statements                                                               F- 59  
  Consolidated Statements of Comprehensive Income                                              F- 60  
  As at December 31, 2024 and December 31, 2023:                                                      
  Consolidated Statements of Financial Position                                                F- 61  
  For the Years Ended December 31, 2024, 2023 and 2022:                                               
  Consolidated Statements of Changes in Equity                                                 F- 62  
  Consolidated Statements of Cash Flows                                                        F- 63  
  Notes to the Consolidated Financial Statements                                               F- 64  

F-1

Table of Contents

Report of Independent Registered Public Accounting Firm

To the Board of Directors and Shareholders of HUTCHMED (China) Limited

Opinions on the Financial Statements and Internal Control over Financial Reporting

We have audited the accompanying consolidated balance sheets of HUTCHMED (China) Limited and its subsidiaries (the“ Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations, of comprehensive income/(loss), of changes in shareholders’ equity and of cash flows for each of the three years in the period ended December 31, 2024, including the related notes (collectively referred to as the“consolidated financial statements”). We also have audited the Company’ s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control - Integrated Framework(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024 in conformity with accounting principles generally accepted in the